Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Social Stream



Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF): $2.22

0.04 (-1.77%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add CANF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#73 of 382

in industry

CAN-FITE BIOPHARMA LTD (CANF) Price Targets From Analysts

Use the tables below to see what analysts covering CAN-FITE BIOPHARMA LTD think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-09-13 2 $50 $50 $50 $2.06 2327.18%
2022-11-29 2 $5 $5 $5 $2.06 142.72%
2022-12-12 2 $8 $5 $6.5 $2.06 215.53%
2023-01-27 2 $34 $34 $34 $2.06 1550.49%
2023-06-02 2 $34 $6 $20 $2.06 870.87%
2023-08-31 2 $34 $6 $17.333 $2.06 741.41%
2023-11-03 2 $18 $6 $12 $2.06 482.52%

The Trend in the Analyst Price Target


CANF's average price target has moved up $7 over the prior 16 months.

CANF reports an average of 618.09% for its upside potential over the past 40 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-05-01 2 34 6 20 1.750 1042.86%
2023-05-30 2 34 6 20 2.465 711.36%
2023-06-02 2 34 6 20 2.790 616.85%
2023-10-24 2 18 6 12 1.950 515.38%
2023-11-03 2 18 6 12 2.175 451.72%

CANF Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 2 0 0 0 0 2

The Trend in the Broker Recommendations


CANF's average broker recommendation rating improved by 0 over the prior 48 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CANF as an investment opportunity.

  • CAN-FITE BIOPHARMA LTD's number of analysts covering the stock is greater than 19.81% of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, CAN-FITE BIOPHARMA LTD's upside potential (average analyst target price relative to current price) is higher than 656.03% of them.
  • To contextualize these metrics, consider that out of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's variance in analysts' estimates is lower than -247.34% of them.
  • To contextualize these metrics, consider that out of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's average analyst price target is greater than 443.53% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to CAN-FITE BIOPHARMA LTD are BLRX, GLMD, and EDSA.

Is CANF a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!